Cancer News

Avelumab Immunotherapy Approved for Bladder Cancer (05/15/2017)

Bavencio (Avelumab), a programmed cell death ligand–1 (PD L1) inhibitor, has been approved for treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Discuss this article with other patients and caregivers- CancerConnect. About Urothelial Cancer Bladder …

Continue reading "Avelumab Immunotherapy Approved for Bladder Cancer"

FDA Approves Imfinzi for Treatment of Urothelial Cancer (05/11/2017)

The US Food and Drug Administration (FDA) today granted accelerated approval to Imfinzi (durvalumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of treatment with that chemotherapy. Bladder cancer is the most common type …

Continue reading "FDA Approves Imfinzi for Treatment of Urothelial Cancer"

FDA Approves Opdivo for Treatment of Bladder Cancer (02/16/2017)

The US Food and Drug Administration (FDA) today approved Opdivo, (nivolumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed during a period of up to 1 year after first-line platinum-containing chemotherapy. Bladder cancer will be diagnosed in approximately 77,000 people in the United States this year alone. …

Continue reading "FDA Approves Opdivo for Treatment of Bladder Cancer"

Tecentriq® Approved for Bladder Cancer (06/08/2016)

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved for the treatment of bladder cancer. Urothelial carcinoma (formerly known as transitional cell carcinoma) is … Continue reading "Tecentriq® Approved for Bladder Cancer"

Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer (06/08/2016)

The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Bladder cancer will be diagnosed in approximately 77,000 people in … Continue reading "Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer"

Atezolizumab Provides Long-Lasting Anti-Cancer Responses in Advanced Bladder Cancer (01/21/2016)

The immunotherapeutic agent, atezolizumab, which is still in investigative stages, provides high rates of anti-cancer responses among patients with advanced bladder cancer. These results were recently presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU). Urothelial carcinoma (formerly known as transitional cell carcinoma) is a cancer involving parts … Continue reading "Atezolizumab Provides Long-Lasting Anti-Cancer Responses in Advanced Bladder Cancer"